LIU Xin-yu, REN Sheng-xiang, DONG Song. Immunotherapy Opens a New Chapter of Adjuvant Therapy, and Precise Strategy Exploration Has a Long Way To Go: Comment on the Opportunities and Challenges of Neoadjuvant Immunotherapy in NSCLC[J]. Journal of Evidence-Based Medicine, 2024, 24(1): 12-15. DOI: 10.12019/j.issn.1671-5144.2024.01.002
|
Citation:
|
LIU Xin-yu, REN Sheng-xiang, DONG Song. Immunotherapy Opens a New Chapter of Adjuvant Therapy, and Precise Strategy Exploration Has a Long Way To Go: Comment on the Opportunities and Challenges of Neoadjuvant Immunotherapy in NSCLC[J]. Journal of Evidence-Based Medicine, 2024, 24(1): 12-15. DOI: 10.12019/j.issn.1671-5144.2024.01.002
|
LIU Xin-yu, REN Sheng-xiang, DONG Song. Immunotherapy Opens a New Chapter of Adjuvant Therapy, and Precise Strategy Exploration Has a Long Way To Go: Comment on the Opportunities and Challenges of Neoadjuvant Immunotherapy in NSCLC[J]. Journal of Evidence-Based Medicine, 2024, 24(1): 12-15. DOI: 10.12019/j.issn.1671-5144.2024.01.002
|
Citation:
|
LIU Xin-yu, REN Sheng-xiang, DONG Song. Immunotherapy Opens a New Chapter of Adjuvant Therapy, and Precise Strategy Exploration Has a Long Way To Go: Comment on the Opportunities and Challenges of Neoadjuvant Immunotherapy in NSCLC[J]. Journal of Evidence-Based Medicine, 2024, 24(1): 12-15. DOI: 10.12019/j.issn.1671-5144.2024.01.002
|
DownLoad: